LifeStyle

The FINANCIAL -- Pfizer Inc. on April 19 announced positive top-line results from the Phase 3 PALOMA-2 trial for IBRANCE (palbociclib), an oral, first-in-class inhibitor of cyclin-dependent kinases (CDKs) 4 and 6.1 The study met its primary endpoint by demonstrating an improvement in progression-free survival (PFS) for the combination of IBRANCE plus letrozole compared with letrozole plus placebo ...

The FINANCIAL -- InterContinental Hotels Group (IHG) announces the opening of the new-build 188-room Holiday Inn & Suites Leon Plaza Mayor hotel. This hotel, following a more than $260 million ...